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ABSTRACT 
Austria notified the European Commission of its new scientific elements justifying the prolongation for three 
additional years of the implementation of a national safeguard measure prohibiting the placing on the market of 
genetically modified maize MON 863 in Austria. Subsequently, the European Commission asked the European 
Food Safety Authority (EFSA) to assess the new scientific information supporting the prolongation of the 
prohibition. Having considered the information provided by Austria and all relevant scientific publications, the 
EFSA Panel on Genetically Modified Organisms (GMO Panel) concluded that the new scientific elements 
submitted by the Austrian Authorities do not lead EFSA to reconsider the conclusions in its opinions on maize 
MON 863. 
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SUMMARY 
Following a request from the European Commission (EC), the Panel on Genetically Modified 
Organisms (GMO Panel) was asked to deliver a scientific opinion on the new scientific information 
provided by Austria to support the prolongation of prohibition for the placing on the market of 
genetically modified (GM) maize MON 863 in Austria. 
In November 2012, Austria notified the EC of its scientific elements justifying prolongation of its 
national safeguard measure prohibiting the placing on the market of GM maize MON 863 in Austria. 
On 13 March 2013, the European Food Safety Authority (EFSA) was requested by the EC to assess 
the new scientific information submitted by the Austrian Authorities justifying prolongation of their 
national safeguard measure concerning maize MON 863. 
In the light of the information provided by Austria in support of the prolongation of its safeguard 
clause, and having considered all relevant scientific publications, the GMO Panel concluded that the 
new scientific elements submitted by the Austrian Authorities do not lead EFSA to reconsider the 




Scientific Opinion on prolongation of safeguard clause by Austria on GM maize MON 863  
 
EFSA Journal 2013;11(11):3454 3 
TABLE OF CONTENTS 
Abstract .................................................................................................................................................... 1 
Summary .................................................................................................................................................. 2 
Table of contents ...................................................................................................................................... 3 
Background as provided by the European Commission ........................................................................... 4 
Terms of reference as provided by the European Commission ................................................................ 4 
Assessment ............................................................................................................................................... 5 
1. Introduction ..................................................................................................................................... 5 
2. Summary of concerns raised by Austria .......................................................................................... 5 
3. Frequency of environmental antibiotic resistance and the risk assessment of the nptII gene ......... 5 
3.1. Prevalence of nptII in human pathogen isolates ....................................................................... 5 
3.2. Prevalence of nptII in soil samples ........................................................................................... 6 
3.3. Prevalence of nptII in feed samples .......................................................................................... 7 
3.4. Mosaic genes ............................................................................................................................. 7 
3.5. Antibiotic selection pressure and model for horizontal gene transfer ....................................... 8 
4. Toxicological risk assessment ......................................................................................................... 8 
4.1. Issues related specifically to maize MON 863 .......................................................................... 8 
4.2. General issues raised ................................................................................................................. 9 
Conclusions ............................................................................................................................................ 10 
Documentation provided to EFSA ......................................................................................................... 10 
References .............................................................................................................................................. 10 
Scientific Opinion on prolongation of safeguard clause by Austria on GM maize MON 863  
 
EFSA Journal 2013;11(11):3454 4 
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
MON 863 maize is authorised in the European Union for food and feed containing, consisting of, or 
food produced from MON 863 (with the exception of food additives) and for other uses with the 
exception of cultivation. This GM maize is currently under renewal of its authorisation for the food 
additives and feed produced from MON 863. The renewal application received a favourable opinion 
from EFSA in March 2010. 
In March 2009, Austria notified to the Commission the national safeguard measure on maize MON 
863 accompanied by scientific argumentation. In June 2009, EFSA issued a scientific opinion 
concluding that there was no scientific evidence justifying the invocation of a safeguard clause under 
Article 23 of Directive 2001/18/EC for the marketing of maize MON 863 for its intended uses in 
Austria. 
In November 2012, Austria notified to the Commission its Ordinance BGBI. II Nr. 319/2012 of 27 
September 2012 prolonging, for three additional years, the implementation of the national safeguard 
measure on maize MON 863 accompanied by new scientific argumentation. 
In order for the Commission to appropriately follow-up on this safeguard clause, it was deemed 
appropriate for EFSA to assess the new scientific elements provided by Austria to justify its decision. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
EFSA was requested in accordance with Article 29 of Regulation (EC) No 178/2002 to assess the new 
scientific information submitted by the Austrian Authorities justifying prolongation of their national 
safeguard measure concerning GM maize MON 863 and to identify whether these new scientific 
elements might lead the EFSA to reconsider its related opinions on GM maize MON 863. 
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ASSESSMENT 
1. Introduction 
Directive 2001/18/EC allows the Member States to invoke safeguard measures on specific genetically 
modified organisms (GMOs) in the case where new or additional information, made available since 
the date of the consent, or reassessment of existing information on the basis of new or additional 
scientific knowledge would affect the risk assessment of an authorised GMO. Austria seeks to 
provisionally prohibit the marketing of maize MON 863 in Austria. 
The EFSA GMO Panel examined the set of supporting documents submitted by Austria and assessed 
whether the submitted documents provide new scientific information that would change the outcome 
of previous risk assessments and lead the GMO Panel to reconsider its opinions on GM maize MON 
863 (EFSA, 2004a, 2009a). 
The GMO Panel looked for evidence of GMO-specific risks, taking into consideration the EFSA 
GMO Panel Guidance for risk assessment of food and feed from genetically modified plants (EFSA 
GMO Panel, 2011) as well as previous risk assessments related to maize MON 863. In addition, the 
GMO Panel considered the relevance of the concerns raised by Austria in the light of the most recent 
scientific data and relevant peer-reviewed publications regarding the use of specific antibiotic 
resistance genes as marker genes in GM plants. 
A meeting was held on 20 June 2013 between the Austrian delegation and EFSA staff and appointed 
experts. This allowed the argumentation to be presented and facilitated clarifications on issues related 
to the documentation provided by Austria. Following questions by the EFSA experts, Austria provided 
additional information on 31 July 2013 (minutes of the meeting will be published on the EFSA 
website). 
2. Summary of concerns raised by Austria 
The GMO Panel interprets the documentation provided by Austria as raising the following issues: 
 the levels of nptII which occur naturally in Austrian isolates from human clinical samples, and 
in soil and feed samples, were considered by Austria to be low and a long-term exposure of 
these environments to plant DNA carrying nptII might elevate the abundance of this resistance 
determinant (Sections 3.1 and 3.2); 
 transformation of bacteria with plant-derived DNA fragments would have the potential to 
result in the formation of mosaic genes (Section 3.3); 
 as horizontal gene transfer events are difficult to observe, a model was constructed to simulate 
the spread of a novel gene in a bacterial population and the most relevant parameters were 
discussed (Section 3.4);  
 shortcomings in the toxicological risk assessment of maize MON 863 (Section 4). 
3. Frequency of environmental antibiotic resistance and the risk assessment of the nptII 
gene 
3.1. Prevalence of nptII in human pathogen isolates 
Austria reported data on the analysis of the presence of nptII in human clinical isolates collected in 
Austria. These included isolates of Escherichia coli, Enterococcus faecalis, Enterococcus faecium, 
Pseudomonas aeruginosa and Staphylococcus spp. collected during 2010 and 2011 and in Salmonella 
enterica subsp. enterica isolates collected during 2008–2010. A total of approximately 10 400 isolates 
was analysed. None of the isolates carried the nptII gene except for a single Salmonella strain. No 
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further information on the genetic background of resistance in this Salmonella strain has been 
provided. 
Austria concluded that the prevalence of nptII in the human pathogenic strains collected in Austria 
was low and indicative of a resistance gene pool depleted of nptII. Austria argued that such a 
resistance gene pool might be “receptive for additional nptII gene copies from external sources”. It 
was argued further that, although plant to bacteria gene transfer rates are extremely infrequent under 
naturally occurring conditions, long-term and constant exposure of bacteria to DNA containing an 
antibiotic resistance marker (ARM) gene would increase the contact frequency between competent 
bacteria and resistance gene fragments. Therefore, under certain selection conditions, there would be 
the potential to induce changes in the frequency of nptII gene copies in bacterial populations with a 
low endogenous nptII baseline. Austria also concluded that it cannot be entirely excluded that an 
increase in resistant bacteria would occur following an introduction of ARM genes into the accessible 
gene pool of the investigated bacteria. 
The EFSA GMO Panel does not share the concept of a “receptive” gene pool in Austria’s 
argumentation. The GMO Panel reiterates that the distribution of nptII in bacteria, even in cases where 
the prevalence is low, provides opportunities for transfer of this gene within bacterial communities. 
Transfer among bacterial community members occurs by the highly efficient method of conjugation 
and to a lesser extent by transduction or transformation. On the other hand, horizontal gene transfer 
from plant to bacterial DNA has been shown to only occur by transformation, and several factors 
limiting its frequency are recognised (EFSA, 2009b). Accordingly, such transfer would be much less 
likely to occur than that between bacteria, even in bacterial populations with a low level of nptII 
present. 
Data provided by Austria show kanamycin
4
 resistance in human clinical isolates. It should be stressed 
that, in clinical settings, the use of antibiotics is a key factor in the selection and dissemination of 
antibiotic resistance genes among bacteria in the immediate environment (EFSA, 2009b). 
3.2. Prevalence of nptII in soil samples 
Austria submitted data on the analysis of the prevalence of nptII in 100 samples of soils not exposed to 
GM crops. Each sample consisted of a combination of 10 single soil extractions from 50 maize and 50 
potato fields. In the analysis of total DNA per soil sample, the nptII gene was found in 6 % of the 
fields (95 % confidence interval 2.2–12.6 %), with a mean number of copies in the positive samples of 
340 per g of soil (range 31–856). An average of 8.29 % of all cultivable bacteria from 10 fields were 
resistant to kanamycin (range 0.47–19.12 %), but none of the 396 kanamycin-resistant strains isolated 
and characterised carried the nptII gene (95% confidence interval 0–0.8 %). 
Austria concluded that the naturally occurring background load of nptII resistance genes in 
agricultural habitats used for the cultivation of maize and potatoes in Austria was low. Austria argued 
that the resistance gene pools under investigation appear not to be “saturated” but “receptive for the 
input of exogenous DNA carrying aminoglycoside phosphotransferase (3 )-IIa gene homologues”. The 
Austrian Authorities consider that a long-term and constant exposure of these habitats to exogenous 
DNA carrying nptII via root exudates, or following plant decay, might be capable of elevating the 
abundance of this resistance determinant in relevant environments. 
                                                     
4 Kanamycin and neomycin have been recategorised by the WHO from ‘Highly Important Antimicrobial’ to ‘Critically 
Important Antimicrobial’ (WHO, 2012). The GMO Panel reiterates its view that, while some knowledge gaps remain 
regarding the understanding of the natural reservoir of antibiotic resistance genes and their role in natural bacterial 
communities not exposed to industrially produced antibiotics, the key role of selection by antibiotic usage in the 
development of resistance is indisputable (EFSA, 2009b). Therefore, the WHO recategorisation may impact the 
development of bacterial resistance via antibiotic selection pressure (because of change of use) but has no impact on the 
barriers limiting the transfer frequency of nptII from plant to bacterial DNA, which remains several orders of magnitude 
lower than the transfer rates between bacteria. 
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The EFSA GMO Panel does not share the concept of “saturated” and “receptive” in Austria’s 
argumentation. Data provided by Austria show the presence of nptII in the soil samples analysed. In 
any case, the GMO Panel notes that maize MON 863 is not authorised for cultivation in the European 
Union. Therefore, exposure of soil bacteria to DNA containing nptII from maize MON 863 released 
from imported plant material is expected to be very low and not relevant for soil bacterial populations. 
3.3. Prevalence of nptII in feed samples 
Austria reported results from the analysis of the presence of nptII in feed-associated bacteria by testing 
total DNA extracts of dried maize kernels and potato juice (42 samples of each). None of the DNA 
extracts yielded a positive result after PCR targeting the nptII gene. Bacterial populations associated 
with the maize and potato samples were cultured in kanamycin-containing medium and resistant 
strains were isolated and tested for the presence of nptII. One strain out of 167 isolates carried the 
nptII gene. The frequency of the kanamycin resistance phenotype varied considerably, from 0.01 % to 
73.05 % in maize samples and from 0.002 % to 6.6 % in potato samples. Austria concluded that, 
although only a small number of bacterial samples were tested, the results support the hypothesis that 
nptII occurrence is low in maize and potatoes cultivated and used as feed in Austria. 
The EFSA GMO Panel reiterates that the distribution of nptII in naturally occurring bacteria provides 
opportunities for transfer of this gene between bacteria by the highly efficient method of conjugation 
and to a lesser extent by transduction or transformation. Horizontal gene transfer from plant to bacteria 
can occur only by transformation, and several factors limiting its frequency are recognised (EFSA, 
2009b). The EFSA GMO Panel therefore stresses that transfer of the nptII gene from plant to bacteria 
would be expected to occur with a frequency several orders of magnitude lower than that between 
bacteria (EFSA, 2009b).  
3.4. Mosaic genes 
Austria reported results from bioinformatic analyses, which showed no extended regions of DNA 
similarity between nptII gene sequences and other aminoglycoside phosphotransferase genes. The 
contiguous stretches of identical sequences were short. Austria concluded that homologous 
recombination between nptII and other aminoglycoside phosphotransferase genes would not be the 
primary route for the exchange of DNA fragments and sequence evolution.  
Austria further investigated the possibility for exchange of DNA sequences between aminoglycoside 
phosphotransferase genes by illegitimate recombination on the basis of regions with microhomologies. 
Sequence alignments using standard parameters of the BLAST algorithm did not reveal the presence 
of nptII mosaic genes of natural origin in GenBank sequence entries. Data retrieved from 
bioinformatic analysis did not support the hypothesis of an involvement of the nptII gene in the 
formation of mosaic genes with altered resistance patterns within the family of aminoglycoside 
phosphotransferases. 
Austria also investigated, experimentally, the potential for nptII to generate mosaic genes with related 
phosphotransferase genes. In a first step, the natural aph(3 )-Ib or aph(3 )-Va gene was introduced 
into the genome of Acinetobacter baylyi bacterium. Subsequently, these strains containing either the 
aph(3 )-Ib or the aph(3 )-Va gene were transformed with linearised plasmids containing nptII flanked 
on one side by a stretch of DNA (anchor) homologous to Acinetobacter baylyi genomic DNA flanking 
the genes introduced in the first step, thus potentially facilitating homologous recombination. No 
transformants were obtained with the Acinetobacter baylyi containing the aph(3 )-Ib sequence. 
Transformation of Acinetobacter baylyi containing the aph(3 )-Va sequence yielded colonies with 
decreased susceptibility to kanamycin as analysed by a disc diffusion test. Austria argued that 
“recombination has likely occurred between the two genes, as it would be the case with the formation 
of mosaic genes”. Austria concluded that the phenotypic data obtained indicated the induction of an 
increase in resistance to kanamycin after uptake of nptII, involving formation of mosaic structures. No 
sequencing data were provided to support this interpretation. 
Scientific Opinion on prolongation of safeguard clause by Austria on GM maize MON 863  
 
EFSA Journal 2013;11(11):3454 8 
The EFSA GMO Panel agrees with Austria that no mosaic structures of aminoglycoside 
phosphotransferase genes have been reported in bacteria although these genes are widespread in many 
environments. The formation of mosaic structures from the transfer of the nptII gene from plant to 
bacteria would be expected to occur with a frequency several orders of magnitude lower than the 
frequency obtained by transfer of DNA between bacteria. The GMO Panel concludes that the data 
provided do not indicate the existence of mosaic structures of aminoglycoside phosphotransferase 
genes and no new hazard has been identified. 
The GMO Panel considers that Austria’s interpretation of the experimental results of decreased 
susceptibility to kanamycin as a result of the formation of a mosaic gene is premature, and that 
verification would need, as a minimum requirement, the sequence analysis of the colonies with 
reduced susceptibility to the antibiotic. 
3.5. Antibiotic selection pressure and model for horizontal gene transfer  
Since horizontal gene transfers are rare events and thus difficult to observe, Austria constructed a 
model simulating the horizontal transfer of plant-derived antibiotic resistance genes into soil bacterial 
communities, on the basis of results from Townsend et al. (2012). One aim of this modelling exercise 
was to determine which parameters have the largest influence on the outcome. Austria concluded that 
fixation of a new trait is mostly dependent on the selection pressure prevailing in the relevant habitat. 
The frequency of horizontal gene transfer (transfer rate) and the population size also play a (smaller) 
role concerning the fixation of a new trait in a population. 
The GMO Panel reiterates that maize MON 863 is not authorised for cultivation in the European 
Union. Therefore, exposure of soil bacteria to DNA containing nptII from maize MON 863 is 
expected to be very low. The GMO Panel is of the opinion that the exposure levels considered in the 
model are unrealistically high even in the case of cultivation of the GM maize. 
The Panel agrees with Austria that antibiotic selection pressure is a key factor in the selection and 
dissemination of antibiotic resistance genes in bacterial populations. Even if bacteria containing nptII 
are present at a low level in the bacterial gene pool, the transfer rate of nptII between bacteria would 
occur at a frequency several orders of magnitude greater than the rate calculated in laboratory 
conditions for a transfer of plant DNA to bacteria. 
4. Toxicological risk assessment 
The GMO Panel notes that in the concerns detailed below by Austria no new scientific data have been 
provided to support Austria’s claims and no new hazards have been identified. 
4.1. Issues related specifically to maize MON 863 
Concern of Austria: The 90-day toxicity study in rats is based on an OECD test design outdated at the 
time of planning and realisation of the study (thus, certain neuro-/immunotoxic endpoints being 
already state-of-the-art were not investigated). 
The basic requirements according to OECD Guideline 408 have not changed in the 
intervening nine years since the study was reported in 2004. Neurological and immunological 
endpoints are not considered part of the standard battery of observations; they are considered 
optional and triggered by other indications. Since such indications did not exist in the case of 
MON863, the GMO Panel did not consider it necessary to investigate these endpoints. 
Concern of Austria: Significant differences are not classified as biologically relevant (arguments: 
within statistical bandwidth, no dose-related effects, no effects in both sexes, etc.) Further tests to 
investigate potential adverse effects were not carried out (long term studies, 
developmental/reproductive toxicity studies). 
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Each individual endpoint showing significant differences was described and assessed for its 
biological relevance, as documented in the Scientific Opinion of the EFSA GMO Panel 
(EFSA, 2004a). A re-analysis of the data carried out in 2007 came to the same conclusion as 
the previous assessment (EFSA, 2007a, b). 
Concern of Austria: No rationale is given whether 33 % is indeed the highest possible level for maize 
in the diet of rats (accordingly, higher dosages may have been used). 
The applicant, in its notification C/DE/02/9, submitted within the framework of Directive 
2001/18/EC and Regulation 258/97, calculated the mean and 97.5th percentile of maize 
consumption (g/kg body weight per day) in Europe based on UK data (the Nutritional Survey 
of British Adults and the UK National Diet) and found that it is of the same order as the doses 
used in the animal experiment.  
4.2. General issues raised 
Concern of Austria: Studies in broiler chicken are mainly designed to investigate efficacy and 
tolerance and cannot be a substitute for lege artis toxicity studies. 
The GMO Panel agrees with this statement and does not require such studies in its 
toxicological assessment. However, such studies can show differences in endpoints such as 
growth rate, morbidity and mortality between animals fed the GM diet and those fed a 
conventional counterpart diet, which are of relevance to the safety assessment. 
Concern of Austria: Intravenous administration of the trans-proteins does not reflect the natural route 
of exposure.  
The GMO Panel agrees with this comment. It is noted that the comment is not relevant since 
in the context of the most recent application on maize MON 863 (EFSA GMO Panel, 2010) 
no studies with intravenous administration of the newly expressed proteins were provided. 
Concern of Austria: There are some deficits that become apparent in studies performed by the 
applicant and cited by Hammond et al. (2006). 
– The study design provided a majority of reference groups (60–80 %), and thus the data of the verum 
group were potentially masked by comparing to broad ranges in their statistical relevance. 
The EFSA GMO Panel has addressed this point in its statements (EFSA, 2004b, 2007b): in the 
event that statistically relevant changes in biological parameters have been identified, their 
natural variations must be taken into account in order to assess the biological relevance. To 
this end the use of animals of the same strain and age, fed with diets containing other 
commercial maize varieties, is most relevant. 
– Rules of good practice require examination of histo-pathological endpoints. However, these 
requirements were not fully met. 
The statement is not clear. Histo-pathological endpoints, examined by the applicant, have been 
assessed by the EFSA GMO Panel (EFSA, 2004a, b, 2007a, b). 
– Significant differences which had been observed were downgraded using arguments such as “no 
dose-related trends”, “within historical control”, and “pathologically irrelevant”. 
The concept that, while statistics provide a tool to compare treated groups to controls, the 
assessment of the biological importance of any “statistically significant” effect requires a 
broader evaluation of the data is the accepted practice in the toxicological assessment (Wilson 
et al., 2001). 
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CONCLUSIONS 
The EFSA GMO Panel concluded that the new scientific elements presented in the data package 
submitted by the Austrian Authorities do not lead EFSA to reconsider the conclusions in its opinions 
on maize MON 863.  
DOCUMENTATION PROVIDED TO EFSA 
1. Letter, received 13 March 2013, with supporting documents from Ladislav Miko, Deputy 
Director-General for the food chain EC, to Catherine Geslain-Lanéelle, Executive Director EFSA 
(ref. Ares(2013)327179), requesting the assessment by EFSA of the new scientific elements 
provided by Austria in support of its decision to prolong its national safeguard measure under 
Article 23 of Directive 2001/18/EC for GM maize MON 863 and comprising the following 
supporting documents: 
– Frequency of environmental antibiotic resistance, baseline prevalence of neomycin 
phosphotransferase genes II and III in maize and potato fields, feed and human bacterial 
pathogens in Austria 
 Executive summary 
 part A: nptII and nptIII prevalence in human pathogens 
 part B: nptII and nptIII prevalence in soil 
 part C: nptII and nptIII prevalence in feed 
 part D: mosaic genes, selection pressure, modelling horizontal gene transfer in soil 
habitats; 
 part E: PCR detection methods; 
– AGES Englische Fassung/Verlängerung ImportverboteMais MON863, Raps Ms8xRf3, Raps 
GT73 
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